Related Experiment Videos
Lipid-lowering therapy for patients with or at risk of coronary artery disease
J Kjekshus1, T R Pedersen, J A Tobert
1Department of Medicine B, Rikshospitalet, Oslo, Norway.
Insights
Lipid-lowering therapy, including statins like pravastatin, significantly reduces coronary events and improves survival. These therapies effectively slow atherosclerosis progression without impacting noncardiovascular mortality.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Effective lipid-lowering therapy is known to slow atherosclerotic lesion progression.
- Previous studies indicated cholesterol reduction lowers coronary event risk.
Purpose of the Study:
- To confirm and extend previous findings on the benefits of lipid-lowering therapy.
- To evaluate the impact of specific lipid-lowering drugs on cardiovascular outcomes and survival.
Main Methods:
- Analysis of data from the West of Scotland study, the Cholesterol and Recurrent Events study, and the Scandinavian Simvastatin Survival Study.
- Inclusion of over 15,000 patients treated for 5 years with lipid-lowering therapy.
Main Results:
- Significant reduction in major coronary events observed with pravastatin treatment.
- The Scandinavian Simvastatin Survival Study demonstrated improved survival due to lipid-lowering therapy.
- Noncardiovascular mortality was not affected by substantial cholesterol reductions.
Conclusions:
- Lipid-lowering therapy, particularly with hydroxymethylglutaryl-coenzyme A reductase inhibitors, is effective in reducing cardiovascular events and improving survival.
- These therapies slow the progression of atherosclerosis in coronary and carotid arteries.
- The benefits of lipid-lowering therapy are primarily cardiovascular, with no significant impact on noncardiovascular mortality.
Abstract:
Several studies have shown that effective lipid-lowering therapy slows the progression of atherosclerotic lesions in the coronary and carotid arteries. Recent clinical trials have confirmed and extended previous work showing that lowering cholesterol reduces the risk of coronary events. A clear reduction in major coronary events during treatment for 5 years with the hydroxymethylglutaryl-coenzyme A reductase inhibitor pravastatin was observed in the West of Scotland study and in the preliminary results of the Cholesterol and Recurrent Events study. The Scandinavian Simvastatin Survival Study has provided the first unequivocal demonstration of improved survival as a result of lipid-lowering therapy. These three trials, which together included over 15,000 patients studied for 5 years, have provided good evidence that noncardiovascular mortality is not affected by substantial reductions in blood cholesterol.